Table 2.

Immunohistochemical evaluation of markers for tumor infiltrating cells and molecules involved in the proteasome activity.

	PBS + DMSO (mean ± SD)	Bortezomib (mean ± SD)	p Value*
Tumor infiltrating cellsa
CD8	0.27 ± 0.46	3.13 ± 1.30	< 0.0001
CD4	0.33 ± 0.49	1.40 ± 0.74	< 0.0001
CD20	0.13 ± 0.35	1.60 ± 0.83	< 0.0001
F480	0.13 ± 0.35	2.27 ± 0.88	< 0.0001
CD25	0.27 ± 0.46	2.00 ± 1.19	< 0.0001
CD57	0.67 ± 0.72	3.53 ± 0.99	< 0.0001
Vessels markerb
CD34	2.60 ± 1.81	1.27 ± 1.03	0.02
Proteasome proteinsc
PSMA4	2.40 ± 0.83	3.47 ± 0.74	0.001
PSMD4	3.33 ± 0.98	4.87 ± 0.92	0.0001
PSME1	4.53 ± 0.99	3.00 ± 0.93	0.0002
Ubiquitin	4.27 ± 0.96	4.20 ± 1.15	0.864

*Two-tailed Student’s T test.

^aPositive cell count/HPF averaging 5 representative microscopic fields.

^bPositive vessel count/HPF averaging 5 representative microscopic fields.

^cA combined scoring system was used for the IHC evaluation. Specifically, the total score (0–6) was obtained by adding the score associated to the number of positive cells and the score related to the signal intensity. The score associated to the number of positive cells was defined as follow: 0 (1 ≤ Positive cells/HPF), 1 (2 ≤ x ≤ 10 Positive cells/HPF), 2 (11 ≤ x ≤ 20 Positive cells/HPF), 3 (≥ 21 Positive cells/HPF). The score related to the signal intensity was defined as follow: 0 (absent/very low Intensity/HPF), 1 (low Intensity/HPF), 2 (moderate Intensity/HPF), 3 (high Intensity/HPF).